放射性药物治疗的等效药物命名共识
随着放射性药物治疗(RPT)扩展到神经内分泌肿瘤和前列腺癌之外,本文强调理解FDA的505(b)(2)审批路径并建立共享术语的重要性。文章提出「放射性配体等效药物」这一术语,指通过505(b)(2)途径获批的RPT,区别于通过简化新药申请获批的仿制RPT。建立共享术语有助于多学科清晰沟通和知情治疗选择。
要点
- 505(b)(2)途径是核医学产品FDA获批的成熟机制,基于已发表文献和桥接研究。
- 「放射性配体等效药物」指通过505(b)(2)获批的RPT,不同于仿制RPT。
- 共享术语支持多学科沟通,促进知情治疗选择。
核心结论
- 随着RPT扩展,需建立共享术语以支持多学科沟通和知情治疗选择。
研究设计与样本
- 本文为综述,阐述FDA 505(b)(2)审批路径及RPT命名需求。
主要发现
- 505(b)(2)申请适用于与已批准产品相似的药物,由已发表文献和桥接研究支持。
- 该 streamlined 途径可鼓励开发更多治疗选择,促进患者可及性并提高供应链韧性。
关键数值与推荐
- 「放射性配体等效药物」指通过505(b)(2)途径获批的RPT。
- 仿制RPT通过简化新药申请(ANDA)获批。
临床怎么用
- 核医学科医生应理解505(b)(2)途径和「放射性配体等效药物」术语,以促进多学科沟通和治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
As radiopharmaceutical therapy (RPT) expands beyond neuroendocrine tumors and prostate cancer, it is important to understand the U.S. Food and Drug Administration (FDA) approval process and to establish a shared vocabulary for effective communication. The 505(b)(2) New Drug Application is a well-established mechanism for FDA approval of nuclear medicine products. It is an application for drugs that are similar to an approved product, supported by published literature and studies conducted on similar drugs, and bridging studies demonstrating the scientific relevance of the data to the product. This streamlined approval pathway can encourage development of more treatment options, facilitating greater patient access and improved resilience to supply chain disruptions. The evolving RPT landscape necessitates new nomenclature. "Radioligand equivalent" refers to an RPT approved through the 505(b)(2) pathway, distinct from a generic RPT approved through an Abbreviated New Drug Application. Establishing shared terminology supports clear multidisciplinary communication and fosters informed treatment selection.
引用
- Chauhan A, Hendifar AE, El-Haddad G, et al. The Equivalents Are Coming! Developing a Shared Nomenclature for Radiopharmaceutical Therapy of Neuroendocrine Tumors, Prostate Cancer, and Beyond. J Nucl Med. 2026. PMID: 42061947. doi:10.2967/jnumed.126.272026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。